These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

955 related items for PubMed ID: 15913962

  • 1. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA.
    Schizophr Res; 2005 Sep 15; 77(2-3):129-39. PubMed ID: 15913962
    [Abstract] [Full Text] [Related]

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec 15; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 3. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
    Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER.
    J Psychopharmacol; 2005 Sep 15; 19(5 Suppl):32-8. PubMed ID: 16144784
    [Abstract] [Full Text] [Related]

  • 4. Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.
    Gopal S, Xu H, Bossie C, Burón JA, Fu DJ, Savitz A, Nuamah I, Hough D.
    Int J Clin Pract; 2014 Dec 15; 68(12):1514-22. PubMed ID: 25358867
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
    J Clin Psychiatry; 2004 Aug 15; 65(8):1084-9. PubMed ID: 15323593
    [Abstract] [Full Text] [Related]

  • 6. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O.
    J Clin Psychiatry; 2003 Oct 15; 64(10):1250-7. PubMed ID: 14658976
    [Abstract] [Full Text] [Related]

  • 7. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F, Schreiner A, Thomas P, Sherif T.
    Clin Drug Investig; 2012 Apr 01; 32(4):267-79. PubMed ID: 22339430
    [Abstract] [Full Text] [Related]

  • 8. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
    Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA.
    Am J Psychiatry; 2000 Jul 01; 157(7):1150-5. PubMed ID: 10873925
    [Abstract] [Full Text] [Related]

  • 9. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W.
    J Psychopharmacol; 2005 Sep 01; 19(5 Suppl):5-14. PubMed ID: 16144781
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA.
    J Affect Disord; 2004 Dec 01; 83(2-3):263-75. PubMed ID: 15555724
    [Abstract] [Full Text] [Related]

  • 11. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.
    Encephale; 2013 May 01; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [Abstract] [Full Text] [Related]

  • 12. Neurological Adverse Effects of Antipsychotics in Children and Adolescents.
    Garcia-Amador M, Merchán-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J, Baeza I, de la Serna E, Alda JA, Muñoz D, Andrés Nestares P, Cantarero CM, Arango C.
    J Clin Psychopharmacol; 2015 Dec 01; 35(6):686-93. PubMed ID: 26505569
    [Abstract] [Full Text] [Related]

  • 13. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH.
    Am J Psychiatry; 1997 Sep 01; 154(9):1248-54. PubMed ID: 9286184
    [Abstract] [Full Text] [Related]

  • 14. Long-acting risperidone in stable patients with schizoaffective disorder.
    Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Bräunig P, Medori R.
    J Psychopharmacol; 2005 Sep 01; 19(5 Suppl):22-31. PubMed ID: 16144783
    [Abstract] [Full Text] [Related]

  • 15. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.
    Pharmacopsychiatry; 2007 Nov 01; 40(6):257-63. PubMed ID: 18030649
    [Abstract] [Full Text] [Related]

  • 16. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM, Yu SC, Lin CC.
    J Clin Psychiatry; 2003 Nov 01; 64(11):1342-8. PubMed ID: 14658949
    [Abstract] [Full Text] [Related]

  • 17. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
    Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M.
    Int J Geriatr Psychiatry; 2000 Jun 01; 15(6):506-14. PubMed ID: 10861916
    [Abstract] [Full Text] [Related]

  • 18. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 19. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
    Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ.
    Int J Neuropsychopharmacol; 2005 Sep 01; 8(3):427-38. PubMed ID: 15804371
    [Abstract] [Full Text] [Related]

  • 20. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
    Rajarethinam R, Dziuba J, Manji S, Pizzuti A, Lachover L, Keshavan M.
    World J Biol Psychiatry; 2009 Sep 01; 10(4 Pt 2):416-9. PubMed ID: 19492247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.